File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Patient-derived tumor organoid cultures identify a chemo-resistant sub-population in esophageal squamous cell carcinoma

TitlePatient-derived tumor organoid cultures identify a chemo-resistant sub-population in esophageal squamous cell carcinoma
Authors
Issue Date2022
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/
Citation
Proceedings of the American Association for Cancer Research (AACR) 113th Annual Meeting, New Orleans, USA, 8-13 April,2022. In Cancer Research, 2022, v. 82 n. 12, Suppl., abstract 6016 How to Cite?
AbstractBackground: Patient-derived xenograft has been a gold standard for cancer modeling. However, low establishment efficiency and high maintenance cost have hindered the development in the field. In recent years, patient-derived tumor organoid culture has been developed as an efficient and economic model to mimic and recapitulate the original tumor tissue, in contrast to conventional cancer cell lines and patient-derived xenografts (Drost & Clevers, 2018). Due to the limited availability of current esophageal squamous cell carcinoma (ESCC) models, we aimed to establish a panel of ESCC patient-derived organoid (PDO) long-term cultures for ESCC study. Results: In the current project, we have established and biobanked a panel of ESCC PDO cultures in vitro from Chinese ESCC treatment-naïve patients undergoing an endoscopic examination or upfront surgery, or patients undergoing neoadjuvant chemoradiotherapy (CRT) followed by surgery in Hong Kong. We also established and maintained PDO-derived xenograft (PDOX) in immunocompromised mice. Immunohistochemical examination confirmed the squamous origin of the established PDOs and PDOXs. Genomic profiling showed consistent mutational landscapes of the established PDO, as compared to ESCC patient profiles. Transcriptomic profiling suggests organoid culture resembles patient tissue samples better than the cell line model in terms of global gene expression patterns. Notably, PDOs from CRT-treated patients show enhanced re-growth after recovery from cisplatin treatment, indicating a candidate cancer stem cell (CSC) sub-population enriched by neoadjuvant CRT. This sub-population can be further enriched in vitro by serial cisplatin treatment and recovery cycles. Conclusions: ESCC PDOs can be efficiently established from highly limited patient tissue samples and maintained long-term in vitro and can be feasibly integrated with mouse model. It preserves the original cell hierarchy and indicates existence of candidate CSC sub-population, which may be targeted therapeutically in future. Reference: Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018 Jul; 18(7).
DescriptionE-Poster - Session OPO.TB01.01 - Nonclinical Models of Cancer - abstract no. 6016
Persistent Identifierhttp://hdl.handle.net/10722/313458
ISSN
2023 Impact Factor: 12.5
2023 SCImago Journal Rankings: 3.468

 

DC FieldValueLanguage
dc.contributor.authorYu, Z-
dc.contributor.authorLUNG, BCC-
dc.contributor.authorSO, SS-
dc.contributor.authorLee, NPY-
dc.contributor.authorWong, IYH-
dc.contributor.authorWong, CLY-
dc.contributor.authorChan, SY-
dc.contributor.authorLaw, SYK-
dc.contributor.authorLung, ML-
dc.date.accessioned2022-06-17T06:46:42Z-
dc.date.available2022-06-17T06:46:42Z-
dc.date.issued2022-
dc.identifier.citationProceedings of the American Association for Cancer Research (AACR) 113th Annual Meeting, New Orleans, USA, 8-13 April,2022. In Cancer Research, 2022, v. 82 n. 12, Suppl., abstract 6016-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/313458-
dc.descriptionE-Poster - Session OPO.TB01.01 - Nonclinical Models of Cancer - abstract no. 6016-
dc.description.abstractBackground: Patient-derived xenograft has been a gold standard for cancer modeling. However, low establishment efficiency and high maintenance cost have hindered the development in the field. In recent years, patient-derived tumor organoid culture has been developed as an efficient and economic model to mimic and recapitulate the original tumor tissue, in contrast to conventional cancer cell lines and patient-derived xenografts (Drost & Clevers, 2018). Due to the limited availability of current esophageal squamous cell carcinoma (ESCC) models, we aimed to establish a panel of ESCC patient-derived organoid (PDO) long-term cultures for ESCC study. Results: In the current project, we have established and biobanked a panel of ESCC PDO cultures in vitro from Chinese ESCC treatment-naïve patients undergoing an endoscopic examination or upfront surgery, or patients undergoing neoadjuvant chemoradiotherapy (CRT) followed by surgery in Hong Kong. We also established and maintained PDO-derived xenograft (PDOX) in immunocompromised mice. Immunohistochemical examination confirmed the squamous origin of the established PDOs and PDOXs. Genomic profiling showed consistent mutational landscapes of the established PDO, as compared to ESCC patient profiles. Transcriptomic profiling suggests organoid culture resembles patient tissue samples better than the cell line model in terms of global gene expression patterns. Notably, PDOs from CRT-treated patients show enhanced re-growth after recovery from cisplatin treatment, indicating a candidate cancer stem cell (CSC) sub-population enriched by neoadjuvant CRT. This sub-population can be further enriched in vitro by serial cisplatin treatment and recovery cycles. Conclusions: ESCC PDOs can be efficiently established from highly limited patient tissue samples and maintained long-term in vitro and can be feasibly integrated with mouse model. It preserves the original cell hierarchy and indicates existence of candidate CSC sub-population, which may be targeted therapeutically in future. Reference: Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018 Jul; 18(7).-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://cancerres.aacrjournals.org/-
dc.relation.ispartofCancer Research-
dc.relation.ispartofAmerican Association for Cancer Research (AACR) Annual Meeting-
dc.titlePatient-derived tumor organoid cultures identify a chemo-resistant sub-population in esophageal squamous cell carcinoma-
dc.typeConference_Paper-
dc.identifier.emailYu, Z: zvyu@hku.hk-
dc.identifier.emailLaw, SYK: slaw@hku.hk-
dc.identifier.emailLung, ML: mlilung@hku.hk-
dc.identifier.authorityYu, Z=rp02756-
dc.identifier.authorityLaw, SYK=rp00437-
dc.identifier.authorityLung, ML=rp00300-
dc.description.natureabstract-
dc.identifier.doi10.1158/1538-7445.AM2022-6016-
dc.identifier.hkuros333589-
dc.identifier.volume82-
dc.identifier.issue12, Suppl.-
dc.identifier.spageabstract 6016-
dc.identifier.epageabstract 6016-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats